Cerebrospinal Fluid Analysis in Psychiatry - Multicentric, prospective patient registry for cerebrospinal fluid analysis in psychiatric patients

Conditions: ICD-10 F*: Mental and behavioral disorders
incl. planned lumbar punctureICD-10
patients who receive a lumbar puncture as part of a neurological exclusion diagnosis

Registration Number: DRKS00024041

Lead Sponsor: Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 200

Inclusion Criteria

1) Patients who have a mental and/or behavioral disorder (ICD-10 F*) and receive a lumbar puncture (i.e., a medical procedure to collect cerebrospinal fluid) as part of the diagnosis; 2) Control group: Patients whom CSF is analyzed due to a neurological exclusion diagnosis (e.g., in case of headache) and in whom a mental and/or behavioral disorder (ICD-10 F*) has been excluded; 3) Age = 18 years; 4) Informed consent that is signed by the patient or his/her legal caregiver/supervisor

Exclusion Criteria

1) Patients who are unable to consent, who do not understand the background and significance and consequences of the study, or whose legal caregiver/supervisor is unwilling to consent; 2) Control group: psychiatric disease (ICD-10 F*)

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence and type of CSF abnormalities occurring in psychiatric patients, as well as the provision of data for further scientific investigations. Development of guidelines for CSF analysis in psychiatry and thus an improvement of the current diagnostic practice and health care for patients with neuropsychiatric diseases.

Secondary Outcome Measures

Name	Time	Method
1. Collecting the following data:<br>a) indication of the lumbar puncture,<br>b) prevalence and unwanted adverse reactions of the lumbar puncture, <br>c) type and frequency of pathological CSF abnormalities; <br>2. Identifying biomarkers in CSF and serum